Nevertheless, the pharmacological inactivation of TP53 cannot be considered a promising therapeutic approach, not only for its potential tumor-promoting effects but also because the CITK phenotype clearly involves a significant TP53-independent component [15, 18]. The gene discussed is TP53; the disease is neoplasm.